Publications
Selected Publications
Nyquist MD, et al. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. J Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. Erratum for: Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. PMID: 34128479; PMCID: PMC8203444.
Brady L, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nature communications. 2021;12(1):1426. Epub 2021/03/05. doi: 10.1038/s41467-021-21615-4. PubMed PMID: 33658518
Bluemn EG, et al. Androgen Receptor Pathway-Independent Prostate Cancer is Sustained through FGF Signaling. Cancer Cell. 2018 Oct 9;32(4):474-489. PMID: 29017058.
Sun Y, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012 Sep; 18(9):1359-68. PMID: 22863786.
Kumar A, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016 Apr;22(4):369-78. PMID: 26928463
Pritchard CC, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine. 2016 Aug 4;375(5):443-53. PMID: 27433846.
Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21;161(5):1215-28. PMID: 26000489
Lucas JM, et al. The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis. Cancer Discov. 2014 Nov;4(11):1310-25. PMID: 25122198
2024
2023
2022
35695870; PMCID: PMC9378683.2021
De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS. Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789. PMID: 34877933; PMCID: PMC8675196.
Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Alaiwi SA, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrisey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 Oct 1;12(1):5775. doi: 10.1038/s41467-021-26042-z. PMID: 34599169; PMCID: PMC8486778.
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13. PMID: 34516663; PMCID: PMC8563438.
Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Yeji Kim J, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, Karnes RJ, Luo J, Antonarakis ES, Nelson PS, Feng FY, Rubin MA, De Marzo AM, Rabadan R, Sims PA, Mitrofanova A, Abate-Shen C. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer. 2020 Nov;1(11):1082-1096. doi: 10.1038/s43018-020-00125-0. Epub 2020 Oct 19. PMID: 34085047; PMCID: PMC8171279.
Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. JAMA Oncol. 2021 Jun 4;7(9):1–5. doi: 10.1001/jamaoncol.2021.2350. Epub ahead of print. PMID: 34086042; PMCID: PMC8446811.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. Erratum for: J Clin Invest. 2021 May 17;131(10): PMID: 34128479; PMCID: PMC8203444.
Bello T, Paindelli C, Diaz-Gomez LA, Melchiorri A, Mikos AG, Nelson PS, Dondossola E, Gujral TS. Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2021 Oct 5;118(40):e2103623118. doi: 10.1073/pnas.2103623118. Epub 2021 Sep 30. PMID: 34593636; PMCID: PMC8501846.
Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer. Cancer Res. 2021 Jul 26:canres.0307.2021. doi: 10.1158/0008-5472.CAN-21-0307. Epub ahead of print. PMID: 34312180.
Genomic and phenotypic heterogeneity in prostate cancer. Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. PMID: 33328650; PMCID: PMC7969494.
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Prostate. 2021 Sep 13. doi: 10.1002/pros.24236. Epub ahead of print. PMID: 34516663.
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Cancer. 2021 Sep 13. doi: 10.1002/cncr.33911. Epub ahead of print. PMID: 34516660.
RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer. Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. Cancer Res. 2021 Jul 26:canres.0307.2021. doi: 10.1158/0008-5472.CAN-21-0307. Epub ahead of print. PMID: 34312180.
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B. JAMA Oncol. 2021 Jun 4. doi: 10.1001/jamaoncol.2021.2350. Epub ahead of print. PMID: 34086042.
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. J Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. Erratum for: Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. PMID: 34128479; PMCID: PMC8203444.
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Kim DH, Sun D, Storck WK, Welker Leng KR, Jenkins C, Coleman DJ, Sampson DA, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman J, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman I, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. Clin Cancer Res. 2021 Jun 18:clincanres.4968.2020. doi: 10.1158/1078-0432.CCR-20-4968. Epub ahead of print. PMID: 34145028.
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT. JCI insight. 2021. Epub 2021/03/17. doi: 10.1172/jci.insight.146827. PubMed PMID: 33724955.
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS. Nature communications. 2021;12(1):1426. Epub 2021/03/05. doi: 10.1038/s41467-021-21615-4. PubMed PMID: 33658518
MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, Rowley DR, Nelson PS, Moore DD, Yang F. The Journal of clinical investigation. 2021;131(4). Epub 2021/02/16. doi: 10.1172/jci135465. PubMed PMID: 33586682
Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Oncogene. 2021;40(11):2148. Epub 2021/02/11. doi: 10.1038/s41388-021-01640-9. PubMed PMID: 33564077.
Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Lin DW, Corey E, Nelson PS, Morrissey C. PloS one. 2021;16(1):e0245602. Epub 2021/01/21. doi: 10.1371/journal.pone.0245602. PubMed PMID: 33471819
Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence? Lin DW, Nelson PS. JAMA oncology. 2021;7(1):59-60. Epub 2020/11/26. doi: 10.1001/jamaoncol.2020.6045. PubMed PMID: 33237305.
Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. Schweizer MT, Cheng HH, Nelson PS, Montgomery RB. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38(32):3740-2. Epub 2020/09/09. doi: 10.1200/jco.20.01755. PubMed PMID: 32897829.
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT. PloS one. 2020;15(9):e0239686. Epub 2020/10/01. doi: 10.1371/journal.pone.0239686. PubMed PMID: 32997692
FOXA2 promotes prostate cancer growth in the bone. Connelly ZM, Jin R, Zhang J, Yang S, Cheng S, Shi M, Cates JM, Shi R, DeGraff DJ, Nelson PS, Liu Y, Morrissey C, Corey E, Yu X. American journal of translational research. 2020;12(9):5619-29. Epub 2020/10/13. PubMed PMID: 33042443
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. Epub 2020/11/18. doi: 10.1158/1078-0432.ccr-20-3396. PubMed PMID: 33199493
Genomic and phenotypic heterogeneity in prostate cancer. Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Nature reviews Urology. 2020. Epub 2020/12/18. doi: 10.1038/s41585-020-00400-w. PubMed PMID: 33328650.
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, Klemfuss NM, Beightol M, Yu EY, Nelson PS, Montgomery B, Pritchard CC. JAMA oncology. 2020. Epub 2020/11/06. doi: 10.1001/jamaoncol.2020.5161. PubMed PMID: 33151258
Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence? Lin DW, Nelson PS. JAMA oncology. 2020. Epub 2020/11/26. doi: 10.1001/jamaoncol.2020.6045. PubMed PMID: 33237305
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. Nature communications. 2020;11(1):6080. Epub 2020/11/29. doi: 10.1038/s41467-020-19486-2. PubMed PMID: 33247092
Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. Potluri HK, Ng TL, Newton MA, Zhang J, Maher CA, Nelson PS, McNeel DG. Journal for immunotherapy of cancer. 2020;8(2). Epub 2020/12/19. doi: 10.1136/jitc-2020-001510. PubMed PMID: 33335027
Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget. Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SA. 2020;11(40):3621-32. Epub 2020/10/23. doi: 10.18632/oncotarget.27736. PubMed PMID: 33088423
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, Newman W, Sirard CA, Fleisher M, Morris MJ, Chen Y, Larson SM, Haffner MC, Nelson PS, Schultz N, Garabedian MJ, Scher HI, Logan SK, Sawyers CL. JCO precision oncology. 2020;4. Epub 2020/10/06. doi: 10.1200/po.20.00097. PubMed PMID: 33015525
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Oncogene. 2020;39(45):6935-49. Epub 2020/09/30. doi: 10.1038/s41388-020-01479-6. PubMed PMID: 32989253
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ. Neoplasia (New York, NY). 2020;22(6):253-62. Epub 2020/05/14. doi: 10.1016/j.neo.2020.04.002. PubMed PMID: 32403054
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. JAMA oncology. 2020:e203187. Epub 2020/08/28. doi: 10.1001/jamaoncol.2020.3187. PubMed PMID: 32852532
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, Erickson S, Alva A, Schweizer MT. PloS one. 2020;15(5):e0233260. Epub 2020/05/27. doi: 10.1371/journal.pone.0233260. PubMed PMID: 32453797
Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography. Hintz HM, Gallant JP, Vander Griend DJ, Coleman IM, Nelson PS, LeBeau AM. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020;26(18):4882-91. Epub 2020/07/09. doi: 10.1158/1078-0432.ccr-20-1358. PubMed PMID: 32636317.
Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H, Brooks JD, Carroll PR, Cooperberg MR, Ellis WJ, Gleave ME, Martin FM, Morgan T, Nelson PS, Wagner AA, Thompson IM, Jr., Lin DW. The Journal of urology. 2020;204(4):701-6. Epub 2020/04/29. doi: 10.1097/ju.0000000000001088. PubMed PMID: 32343189
HPV16 induces penile intraepithelial neoplasia and squamous cell carcinoma in transgenic mice: first mouse model for HPV-related penile cancer. Medeiros-Fonseca B, Mestre VF, Estêvão D, Sánchez DF, Cañete-Portillo S, Fernández-Nestosa MJ, Casaca F, Silva S, Brito H, Félix A, Medeiros R, Colaço B, Oliveira PA, Bastos MM, Nelson PS, Vakar-Lopez F, Gaivão I, Brito L, Lopes C, Cubilla AL, Gil da Costa RM. The Journal of pathology. 2020;251(4):411-9. Epub 2020/06/04. doi: 10.1002/path.5475. PubMed PMID: 32488868.
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Cell reports. 2020;31(8):107669. Epub 2020/05/28. doi: 10.1016/j.celrep.2020.107669. PubMed PMID: 32460015
Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. Schweizer MT, Cheng HH, Nelson PS, Montgomery RB. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020:Jco2001755. Epub 2020/09/09. doi: 10.1200/jco.20.01755. PubMed PMID: 32897829.
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer discovery.Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. 2020;10(6):779-82. Epub 2020/04/12. doi: 10.1158/2159-8290.cd-20-0451. PubMed PMID: 32276929
Targeting RET Kinase in Neuroendocrine Prostate Cancer. Molecular cancer research. VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. :MCR. 2020;18(8):1176-88. Epub 2020/05/29. doi: 10.1158/1541-7786.mcr-19-1245. PubMed PMID: 32461304
A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments. Brady L, Gil da Costa RM, Coleman IM, Matson CK, Risk MC, Coleman RT, Nelson PS. The Prostate. 2020;80(6):491-9. Epub 2020/02/19. doi: 10.1002/pros.23963. PubMed PMID: 32068909.
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020:Jco1902267. Epub 2020/03/05. doi: 10.1200/jco.19.02267. PubMed PMID: 32130059.
Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. Qu X, Yeung C, Coleman I, Nelson PS, Fang M. Cancer genetics. 2020;243:11-8. Epub 2020/03/21. doi: 10.1016/j.cancergen.2020.02.007. PubMed PMID: 32197218.
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown LG, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. Epub 2019/12/07. doi: 10.1158/1078-0432.ccr-19-0775. PubMed PMID: 31806643.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Annals of oncology : official journal of the European Society for Medical Oncology. 2019;30(12):e3. Epub 2016/05/04. doi: 10.1093/annonc/mdw180. PubMed PMID: 27141017.
Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer. Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown L, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. Epub 2019/12/07. doi: 10.1158/1078-0432.ccr-19-0775. PubMed PMID: 31806643.
Exploitation of CD133 for the targeted imaging of lethal prostate cancer. Glumac PM, Gallant JP, Shapovalova M, Li Y, Murugan P, Gupta S, Coleman I, Nelson PS, Dehm SM, LeBeau AM. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. Epub 2019/11/17. doi: 10.1158/1078-0432.ccr-19-1659. PubMed PMID: 31732520.
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS). Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. The Journal of urology. 2019:101097ju0000000000000621. Epub 2019/10/28. doi: 10.1097/ju.0000000000000621. PubMed PMID: 31651227.
PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer. Cancer research. Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman IM, Nelson PS, Dehm SM, LeBeau AM. 2019;79(21):5668-80. Epub 2019/09/19. doi: 10.1158/0008-5472.can-19-2181. PubMed PMID: 31530569.
Molecular determinants of response to high-dose androgen therapy in prostate cancer. Nyquist MD, Corella A, Mohamad O, Coleman I, Kaipainen A, Kuppers DA, Lucas JM, Paddison PJ, Plymate SR, Nelson PS, Mostaghel EA. JCI insight. 2019;4(19). Epub 2019/09/11. doi: 10.1172/jci.insight.129715. PubMed PMID: 31503550.
Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion. Kaipainen A, Zhang A, Gil da Costa RM, Lucas J, Marck B, Matsumoto AM, Morrissey C, True LD, Mostaghel EA, Nelson PS. The Prostate. 2019;79(13):1530-42. Epub 2019/08/04. doi: 10.1002/pros.23874. PubMed PMID: 31376206.
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Science translational medicine. Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. 2019;11(503). Epub 2019/08/02. doi: 10.1126/scitranslmed.aaw4993. PubMed PMID: 31366581.
Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America.Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(23):11428-36. Epub 2019/05/08. doi: 10.1073/pnas.1902651116. PubMed PMID: 31061129.
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EA. Prostate cancer and prostatic diseases. 2019. Epub 2019/03/21. doi: 10.1038/s41391-019-0141-6. PubMed PMID: 30890759.
Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM, Schultz N, Van Allen EM. Nature genetics. 2019;51(7):1194. Epub 2019/06/04. doi: 10.1038/s41588-019-0451-6. PubMed PMID: 31152158.
The role of lineage plasticity in prostate cancer therapy resistance. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. Epub 2019/08/01. doi: 10.1158/1078-0432.ccr-19-1423. PubMed PMID: 31363002.
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM. Nature cell biology. 2019;21(2):238-50. Epub 2019/01/22. doi: 10.1038/s41556-018-0267-0. PubMed PMID: 30664790.
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Goppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.. Cancer cell. 2019;35(3):401-13.e6. Epub 2019/02/19. doi: 10.1016/j.ccell.2019.01.008. PubMed PMID: 30773341.
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS. The Journal of clinical investigation. 2019;130. Epub 2019/07/17. doi: 10.1172/jci127613. PubMed PMID: 31310591.
Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. Gordon JA, Noble JW, Midha A, Derakhshan F, Wang G, Adomat HH, Tomlinson Guns ES, Lin YY, Ren S, Collins CC, Nelson PS, Morrissey C, Wasan KM, Cox ME. Cancer research. 2019;79(13):3320-31. Epub 2019/05/09. doi: 10.1158/0008-5472.can-18-2529. PubMed PMID: 31064850.
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, Gil da Costa RM, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. The Journal of clinical investigation. 2019;130. Epub 2019/07/31. doi: 10.1172/jci128212. PubMed PMID: 31361600.
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E. European urology. 2019. Epub 2019/06/23. doi: 10.1016/j.eururo.2019.05.042. PubMed PMID: 31227306.
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer research. Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. 2019;79(10):2580-92. Epub 2019/04/07. doi: 10.1158/0008-5472.can-18-2812. PubMed PMID: 30952632
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. Munoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, Freund AM, Rodier F, Wu JD, Desprez PY, Raulet DH, Nelson PS, van 't Veer LJ, Campisi J, Coppe JP. JCI insight. 2019;5. Epub 2019/06/12. doi: 10.1172/jci.insight.124716. PubMed PMID: 31184599.
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate cancer and prostatic diseases. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. 2019. Epub 2019/01/22. doi: 10.1038/s41391-018-0124-z. PubMed PMID: 30664734.
Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP. The Prostate. 2019;79(11):1326-37. Epub 2019/06/19. doi: 10.1002/pros.23839. PubMed PMID: 31212368.
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO precision oncology. Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC. 2019;3. Epub 2019/05/28. doi: 10.1200/po.18.00327. PubMed PMID: 31123724.
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC. JCI insight. 2019;5. Epub 2019/05/31. doi: 10.1172/jci.insight.128728. PubMed PMID: 31145100.
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. The EMBO journal. 2019;38(5). Epub 2019/02/07. doi: 10.15252/embj.201899599. PubMed PMID: 30723117.
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR. Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26. PMID: 30478421
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available. PMID: 30382943
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR. J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26. PMID: 30334814
Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP. Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21. PMID: 30242112
The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells. Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman IM, Reed MJ, Nelson PS. Mol Cancer Res. 2019 Jan;17(1):321-331. doi: 10.1158/1541-7786.MCR-18-0522. Epub 2018 Sep 17. PMID: 30224545
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS. Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4. PMID: 30181386
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. PMID: 30179225
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. PLoS One. 2018 Aug 15;13(8):e0202709. doi: 10.1371/journal.pone.0202709. eCollection 2018. PMID: 30110398
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065. PMID: 30076904
A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. Mamouni K, Zhang S, Li X, Chen Y, Yang Y, Kim J, Bartlett MG, Coleman IM, Nelson PS, Kucuk O, Wu D. Neoplasia. 2018 Aug;20(8):789-799. doi: 10.1016/j.neo.2018.06.003. Epub 2018 Jul 4. PMID: 29981500
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP. Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19. PMID: 29921690
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, Zhang Z, Gydush GJ, Rotem D; PCF/SU2C International Prostate Cancer Dream Team, Love JC, Getz G, Gabriel S, Zhang CZ, Dehm SM, Nelson PS, Van Allen EM, Choudhury AD, Adalsteinsson VA, Beroukhim R, Taplin ME, Meyerson M. Cell. 2018 Jul 12;174(2):433-447.e19. doi: 10.1016/j.cell.2018.05.036. Epub 2018 Jun 18. PMID: 29909985
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM. Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034. PMID: 29906450
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. Erratum in: PLoS One. 2018 Aug 15;13(8):e0202709. PMID: 29856824
Microsatellite instability in prostate cancer by PCR or next-generation sequencing. Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC. J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y. PMID: 29665853
The long tail of oncogenic drivers in prostate cancer. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM; PCF/SU2C International Prostate Cancer Dream Team. Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2. PMID: 29610475
Retinol dehydrogenase 11 is essential for the maintenance of retinol homeostasis in liver and testis in mice. Belyaeva OV, Wu L, Shmarakov I, Nelson PS, Kedishvili NY. J Biol Chem. 2018 May 4;293(18):6996-7007. doi: 10.1074/jbc.RA117.001646. Epub 2018 Mar 22. PMID: 29567832
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD. Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19. PMID: 29464091
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9. PMID: 29433975
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9. PMID: 29433973
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS. Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8. PMID: 29429804
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. Chalfin HJ, Glavaris SA, Malihi PD, Sperger JM, Gorin MA, Lu C, Goodwin CR, Chen Y, Caruso EA, Dumpit R, Kuhn P, Lang JM, Nelson PS, Luo J, Pienta KJ. J Urol. 2018 Jun;199(6):1494-1501. doi: 10.1016/j.juro.2018.01.033. Epub 2018 Jan 12. PMID: 29339080
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372. doi: 10.1038/s41391-017-0009-6. Epub 2017 Dec 20. PMID: 29263420
Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA. Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review. PMID: 29210989
PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Geybels MS, Fang M, Wright JL, Qu X, Bibikova M, Klotzle B, Fan JB, Feng Z, Ostrander EA, Nelson PS, Stanford JL. Oncotarget. 2017 Sep 15;8(48):84338-84348. doi: 10.18632/oncotarget.20940. eCollection 2017 Oct 13. PMID: 29137428
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available. PMID: 29088323
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS. Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003. PMID: 29017058
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J. Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1. PMID: 28866255
Prostate Cancer Screening in a New Era of Genetics. Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31. Review. PMID: 28697982
The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer. Sinha S, Nelson PS. Cancer Discov. 2017 Jul;7(7):673-674. doi: 10.1158/2159-8290.CD-17-0481. PMID: 28684411
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. PMID: 28591577
Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Levesque C, Nelson PS. Cold Spring Harb Perspect Med. 2018 Aug 1;8(8). pii: a030510. doi: 10.1101/cshperspect.a030510. Review. PMID: 28490538
Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Mol Cancer Res. 2017 May;15(5):521-531. doi: 10.1158/1541-7786.MCR-16-0315-T. PMID: 28465296
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB. Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7. PMID: 28389510
DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. Gomez-Sarosi L, Sun Y, Coleman I, Bianchi-Frias D, Nelson PS. Mol Cancer Res. 2017 Jul;15(7):842-851. doi: 10.1158/1541-7786.MCR-16-0387. Epub 2017 Mar 29. PMID: 28356331
Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases. Nyquist MD, Nelson PS. Cancer Cell. 2017 Mar 13;31(3):303-305. doi: 10.1016/j.ccell.2017.02.012. PMID: 28292431
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E. Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3. PMID: 28156002
Neoadjuvant Enzalutamide Prior to Prostatectomy. Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9. PMID: 28151719
Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Rubicz R, Zhao S, Wright JL, Coleman I, Grasso C, Geybels MS, Leonardson A, Kolb S, April C, Bibikova M, Troyer D, Lance R, Lin DW, Ostrander EA, Nelson PS, Fan JB, Feng Z, Stanford JL. Mol Oncol. 2017 Feb;11(2):140-150. doi: 10.1002/1878-0261.12014. Epub 2016 Oct 19. PMID: 28145099
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Feng S, Shao L, Castro P, Coleman I, Nelson PS, Smith PD, Davies BR, Ittmann M. Oncotarget. 2017 Jan 24;8(4):6179-6192. doi: 10.18632/oncotarget.14049. PMID: 28008155
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Lam HM, McMullin R, Nguyen HM, Coleman I, Gormley M, Gulati R, Brown LG, Holt SK, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E. Clin Cancer Res. 2017 May 1;23(9):2301-2312. doi: 10.1158/1078-0432.CCR-16-2054. Epub 2016 Dec 19. PMID: 27993966
A proteolytic modification of AIM promotes its renal excretion. Yamazaki T, Sugisawa R, Hiramoto E, Takai R, Matsumoto A, Senda Y, Nakashima K, Nelson PS, Lucas JM, Morgan A, Li Z, Yamamura KI, Arai S, Miyazaki T. Sci Rep. 2016 Dec 8;6:38762. doi: 10.1038/srep38762. PMID: 27929116
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM. Nat Commun. 2016 Nov 29;7:13668. doi: 10.1038/ncomms13668. PMID: 27897170
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators. Eur Urol. 2017 Sep;72(3):448-454. doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23. PMID: 27889277
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD. PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016. PMID: 27846218
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW. J Urol. 2017 Apr;197(4):1026-1033. doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1. PMID: 27810448
DNA-Repair Gene Mutations in Metastatic Prostate Cancer. Pritchard CC, Offit K, Nelson PS. N Engl J Med. 2016 Nov 3;375(18):1804-5. doi: 10.1056/NEJMc1611137. No abstract available. PMID: 27806229
DNA Repair in Prostate Cancer: Biology and Clinical Implications. Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31. Review. PMID: 27590317
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC. Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697. PMID: 27756888
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. Am J Surg Pathol. 2016 Nov;40(11):1439-1456. PMID: 27635949
Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434. Epub 2016 Oct 14. PMID: 27742670
Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Uo T, Dvinge H, Sprenger CC, Bradley RK, Nelson PS, Plymate SR. Oncogene. 2017 Mar;36(10):1440-1450. doi: 10.1038/onc.2016.313. Epub 2016 Oct 3. PMID: 27694897
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. Liss MA, Schenk JM, Faino AV, Newcomb LF, Boyer H, Brooks JD, Carroll PR, Dash A, Fabrizio MD, Gleave ME, Nelson PS, Neuhouser ML, Wei JT, Zheng Y, Wright JL, Lin DW, Thompson IM. Prostate Cancer Prostatic Dis. 2016 Dec;19(4):390-394. doi: 10.1038/pcan.2016.28. Epub 2016 Jul 19. PMID: 27431498
Expression of STAT3 in Prostate Cancer Metastases. Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R, Bjartell A. Eur Urol. 2017 Mar;71(3):313-316. doi: 10.1016/j.eururo.2016.06.018. Epub 2016 Jun 22. PMID: 27344294
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L. Prostate. 2016 Nov;76(15):1409-19. doi: 10.1002/pros.23225. Epub 2016 Jun 21. PMID: 27325561
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.